ABSORB II Randomized Controlled Trial

NACompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

May 23, 2018

Conditions
Coronary Artery Disease
Interventions
DEVICE

Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System

XIENCE implantation in the treatment of coronary artery disease.

DEVICE

Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System

ABSORB BVS implantation in the treatment of coronary artery disease.

Trial Locations (1)

0886.537.933

Abbott Vascular International BVBA, Brussels

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY